Phase II safety and immunogenicity study of quadrivalent human papillomavirus (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine [human papillomavirus vaccine recombinant quadrivalent] in HIV infected children 7 to 12 years of age.

Trial Profile

Phase II safety and immunogenicity study of quadrivalent human papillomavirus (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine [human papillomavirus vaccine recombinant quadrivalent] in HIV infected children 7 to 12 years of age.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms IMPAACT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jun 2013 Sub study status changed from recruiting to active, no longer recruiting according to the ClinicalTrials.gov record.
    • 04 Jun 2013 Sub study status changed from recruiting to active, no longer recruiting according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top